These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 30898538)

  • 1. Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases.
    Zhang X; Hu D; Shang Y; Qi X
    Biochim Biophys Acta Mol Basis Dis; 2020 Apr; 1866(4):165431. PubMed ID: 30898538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases.
    Payne NL; Sylvain A; O'Brien C; Herszfeld D; Sun G; Bernard CC
    N Biotechnol; 2015 Jan; 32(1):212-28. PubMed ID: 24815224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease.
    Wu YY; Chiu FL; Yeh CS; Kuo HC
    Open Biol; 2019 Jan; 9(1):180177. PubMed ID: 30958120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental Cell Models for Investigating Neurodegenerative Diseases.
    Evangelisti C; Ramadan S; Orlacchio A; Panza E
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform.
    Garcia-Leon JA; Vitorica J; Gutierrez A
    Future Med Chem; 2019 Jun; 11(11):1305-1322. PubMed ID: 31161803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms.
    Oksanen M; Lehtonen S; Jaronen M; Goldsteins G; Hämäläinen RH; Koistinaho J
    Cell Mol Life Sci; 2019 Jul; 76(14):2739-2760. PubMed ID: 31016348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced pluripotent stem cells (iPSCs) as game-changing tools in the treatment of neurodegenerative disease: Mirage or reality?
    Yousefi N; Abdollahii S; Kouhbanani MAJ; Hassanzadeh A
    J Cell Physiol; 2020 Dec; 235(12):9166-9184. PubMed ID: 32437029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases.
    Peng J; Zeng X
    Stem Cell Res Ther; 2011 Jul; 2(4):32. PubMed ID: 21861938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models.
    Taoufik E; Kouroupi G; Zygogianni O; Matsas R
    Open Biol; 2018 Sep; 8(9):. PubMed ID: 30185603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Specific iPSCs-Based Models of Neurodegenerative Diseases: Focus on Aberrant Calcium Signaling.
    Grekhnev DA; Kaznacheyeva EV; Vigont VA
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations.
    Kolagar TA; Farzaneh M; Nikkar N; Khoshnam SE
    Curr Stem Cell Res Ther; 2020; 15(2):102-110. PubMed ID: 31441732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling.
    Centeno EGZ; Cimarosti H; Bithell A
    Mol Neurodegener; 2018 May; 13(1):27. PubMed ID: 29788997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.
    Cao L; Tan L; Jiang T; Zhu XC; Yu JT
    Mol Neurobiol; 2015 Aug; 52(1):244-55. PubMed ID: 25146848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening.
    Chang CY; Ting HC; Liu CA; Su HL; Chiou TW; Lin SZ; Harn HJ; Ho TJ
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells.
    Naphade S; Tshilenge KT; Ellerby LM
    Neurotherapeutics; 2019 Oct; 16(4):979-998. PubMed ID: 31792895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics.
    Sen T; Thummer RP
    Neurotox Res; 2022 Oct; 40(5):1597-1623. PubMed ID: 36044181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development.
    Hargus G; Ehrlich M; Hallmann AL; Kuhlmann T
    Acta Neuropathol; 2014 Feb; 127(2):151-73. PubMed ID: 24306942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy Dysfunction as a Phenotypic Readout in hiPSC-Derived Neuronal Cell Models of Neurodegenerative Diseases.
    Sun C; Rosenstock TR; Cohen MA; Sarkar S
    Methods Mol Biol; 2022; 2549():103-136. PubMed ID: 34490597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Importance of Non-neuronal Cell Types in hiPSC-Based Disease Modeling and Drug Screening.
    Gonzalez DM; Gregory J; Brennand KJ
    Front Cell Dev Biol; 2017; 5():117. PubMed ID: 29312938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.